Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week

By Eric Volkman – Mar 27, 2026 at 7:32PM ESTKey PointsIt earned FDA approval for its cancer drug, Lifyorli.This earned a recommendation upgrade from an analyst.One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (CORT 2.41%), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for its leading drug candidate. The double-digit pop Corcept experienced wasn't sustainable, as some investors booked quick profits after learning of the nod. Still, the stock landed in positive territory, posting a gain of just under 9% over the course of the week, according to data compiled by S&P Global Market Intelligence. A bright green light The happy news was announced by Corcept on Wednesday. The product now ready for commercialization in this country is Lifyorli, which has been approved by the American healthcare regulator for use in combination with nab-paclitaxel (a chemotherapy drug) to treat the platinum-resitant stages of fallopian tube, primary peritoneal, and ovarian cancer. Image source: Getty Images. Patients who were previously administered one to three systemic treatment regimes are covered under the FDA's Lifyorli approval. Later on Wednesday, Wolfe Research analyst Kalpit Patel upgraded his recommendation on Corcept stock, from underperform (sell, in other words) to peerperform (hold). According to reports, Patel's change was -- unsurprisingly -- based on the FDA's Lifyorli nod. However, he continues to believe that the biotech's Korlym, a drug used to treat the hormonal disorder Cushing's syndrome, is weighing on its growth potential. ExpandNASDAQ: CORTCorcept TherapeuticsToday's Change(-2.41%) $-0.93Current Price$37.60Key Data PointsMarket Cap$4.1BDay's Range$37.15 - $38.4452wk Range$28.66 - $117.33Volume1.8MAvg Vol2.5MGross Margin98.30% Selling into a high-demand market To a degree, Patel has a point. Yet Corcept's success with Lifyorli not only gives it a marketable drug in a high-demand segment -- cancer -- but it also shows that the company's unique approach to development can work (it focuses on cortisol, the hormone at the heart of Cushing's syndrome). I'd be more bullish than the analyst on Corcept's future.Read NextMar 25, 2026 •By Eric VolkmanWhy Investors Strapped a Rocket to Corcept Therapeutics Stock on WednesdayMar 27, 2026 •By Motley Fool YouTubeNovo Nordisk: A Strong Contender in the Pharmaceutical ArenaMar 27, 2026 •By Eric VolkmanWhy Lenz Therapeutics Stock Plummeted by Almost 20% This WeekMar 27, 2026 •By Prosper Junior BakinyIs Intuitive Surgical a Buy Right Now?Mar 27, 2026 •By Prosper Junior Bakiny2 Stocks I Plan to Hold for the Next 20 YearsMar 27, 2026 •By Alex CarchidiEthereum and Solana Just Got a Huge Catalyst.

Should You Buy Them With $1,000?About the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedCorcept TherapeuticsNASDAQ: CORT$37.60(-2.41%)-$0.93*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.